• In August 2026, Elucent Medical Inc. announced that Knowles Corporation would manufacture its smart surgical guidance device for the EnVisio In-Body Spatial Intelligence System, leveraging Knowles’ precision MedTech capabilities and ISO 13485-certified, FDA-registered facility in Penang, Malaysia.
• This collaboration underscores Knowles’ role as a MedTech manufacturing partner that helps customers improve product reliability, scalability, and time to market through design optimization and cost-effective material sourcing.
• Next, we'll examine how Knowles’ role in manufacturing Elucent’s smart surgical guidance device could influence its MedTech-focused investment narrative.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Knowles Investment Narrative Recap

To own Knowles today, you need to believe in its shift toward higher value MedTech and specialty components while watching margin pressure from product mix and factory costs. The Elucent Medical manufacturing win reinforces the MedTech story but does not fundamentally change the near term margin risk from ramp inefficiencies and higher scrap costs that investors are already focused on.

Among recent developments, the ongoing share repurchase program is most relevant. Knowles has retired more than 17% of its shares since 2020, including US$15.0 million in buybacks in Q2 2026 alone. For investors, that capital return sits alongside MedTech contract wins like Elucent as a key near term catalyst for per share earnings, even as questions remain about the sustainability of margins.

However, even with MedTech momentum, investors should be aware that persistent factory inefficiencies and mix driven margin pressure could...

Knowles' narrative projects $815.9 million revenue and $135.8 million earnings by 2029. This requires 8.7% yearly revenue growth and a $62.6 million earnings increase from $73.2 million today.

Uncover how Knowles' forecasts yield a $43.75 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts took a much more cautious view, even before this Elucent news, assuming about US$830.0 million of revenue and US$132.0 million of earnings by 2029, while also stressing concentration risk in core MedTech customers. Their stance shows how differently you might weigh this new contract, and why it can be helpful to compare several competing narratives before deciding what you believe.

Explore 4 other fair value estimates on Knowles - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Knowles research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Knowles research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Knowles' overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find 50 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.